Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy

NCT01223742 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2010-10-19

No results posted yet for this study

Summary

The aim of this study was to evaluate the effect of exogenous ALC on the both physical and mental fatigue in mild and moderate encephalopatic patients.

Conditions

  • Hepatic Encephalopathy

Interventions

DIETARY_SUPPLEMENT

ACETYL-L-CARNITINE

2 g acetylcarnitine taken orally twice a day.

DRUG

placebo

placebo twice per day

Sponsors & Collaborators

  • University of Catania

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Completion
2006-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223742 on ClinicalTrials.gov